News | Alzheimer's Prevention Registry

You are here

News

Come back regularly for the latest news and information about Alzheimer’s disease and prevention.

I wasn’t yet fully awake this morning when I started poking through my Facebook feed and saw the head-spinning news that Biogen had reversed itself and was now asking the FDA to approve its...
October 16, 2019
by University of Delaware
Amy Bleakley's research runs the gamut from adolescents to Alzheimer's disease, dental cavities to clinical trials, but she says the topics are not as different as they might appear.
Alzheimer’s disease is the only leading cause of death in the U.S. that is still on the rise and that does not have a current effective treatment or cure. The limited inclusion of Latinos...
October 4, 2019
by Science Mag
After some costly and disappointing drug trial failures, the field welcomes a funding surge, tools for tracking disease, and interdisciplinary collaborations to tackle one of science’s most stubborn...
August 21, 2019
by Alzheimer's Prevention Bulletin
In order to get ahead of Alzheimer’s disease earlier, more and more research studies are seeking people without changes to their memory and thinking along with those with a condition known as mild...
In a waiting room at the Banner Alzheimer's Institute in Phoenix, a 74-year-old woman named Rubie is about to find out whether she has a gene that puts her at risk for Alzheimer's.
The Alzheimer’s Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the investigational oral BACE (beta amyloid cleaving enzyme...
Every month, a car would pick up Jeff Borghoff at his home in Forked River, New Jersey, and drive him to the Advanced Memory Research Institute of New Jersey. There, doctors would help him settle...
I was a small piece in the search to find a cure. Now I feel as if I’m getting erased, and medical science doesn’t have any answers.
Clinical trial participants, researchers and investors were reeling on Thursday after Biogen and Eisai, its Japanese pharmaceutical partner, announced that they would be halting two Stage 3...